1. 0
    A Breakout Year for CVRs: 2025 and First-Half 2026 Trends in Life Sciences Public M&A governance corpgov.law.harvard.edu
    via editorial

Three years after our first survey documented the reemergence of contingent value rights (“CVRs”) in public life sciences M&A, 2025 marked their biggest year yet. A record 28 of 59 announced public life sciences transactions (approximately 47%) included a CVR, the highest ever annual count and share. The concentration was even greater in biopharma, where […]

Source: Harvard Law School Forum on Corporate Governance

Published: 2026-09-21T11:30:01Z